News

« Back to News List

June 28, 2013

Bard allegedly knew dangers of TVM device material

A recent, alarming article by Bloomberg suggests that C.R. Bard’s (BCR) Davol unit knew that the plastic it used in its Avaulta line of transvaginal (pelvic) mesh devices was unsafe to be permanently implanted in humans. In addition, e-mails filed in federal court in West Virginia from a Bard executive cautioned fellow colleagues to not notify its suppliers, such as Chevron Phillips, that the company was using the plastic material to create a device to be implanted in humans.

Motley Rice attorneys hold leadership roles in pelvic mesh cases filed in state and federal courts, representing thousands of clients in lawsuits against numerous manufacturers that include Boston Scientific, American Medical Systems, Inc. (AMS), C.R. Bard, Inc., and Johnson & Johnson. Motley Rice member attorney Don Migliori is involved with the trial discussed in the article, In re C.R. Bard Inc. Pelvic Repair System Products Liability Litigation, the federal MDL and four other Bard trials this year, including one in Atlantic City, N.J., in September 2013.

Learn more about how our medical lawyers fight for people hurt by pharmaceutical drugs and medical devices and work to hold accountable those responsible for negligent medical care, corporate wrongdoing, and inadequate warning, research and testing.